keyword
MENU ▼
Read by QxMD icon Read
search

Ankylosing spondyloarthritis

keyword
https://www.readbyqxmd.com/read/28298567/omeract-quality-adjusted-life-years-qaly-working-group-do-current-qaly-measures-capture-what-matters-to-patients
#1
Logan Trenaman, Annelies Boonen, Francis Guillemin, Mickael Hiligsmann, Alison Hoens, Carlo Marra, Will Taylor, Jennifer Barton, Peter Tugwell, George Wells, Nick Bansback
OBJECTIVE: To understand the limitations with current patient-reported outcome measures (PROM) used to generate quality-adjusted life-years (QALY) in rheumatology, and set a research agenda. METHODS: Two activities were undertaken. The first was a scoping review of published studies that have used PROM to generate QALY in rheumatology between 2011 and 2016. The second was an interactive "eyeball test" exercise at Outcome Measures in Rheumatology 13 that compared subdomains of widely used generic PROM, as identified through the scoping review, to subdomains of the Assessment of SpondyloArthritis Health Index (ASAS-HI) condition-specific PROM for ankylosing spondylitis...
March 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28298558/performance-of-3-enthesitis-indices-in-patients-with-peripheral-spondyloarthritis-during-treatment-with-adalimumab
#2
Philip J Mease, Filip Van den Bosch, Joachim Sieper, Yinglin Xia, Aileen L Pangan, In-Ho Song
OBJECTIVE: To evaluate the validity of enthesitis indices in patients with peripheral spondyloarthritis (pSpA). METHODS: The ABILITY-2 study evaluated the efficacy of adalimumab (ADA) versus placebo (PBO) in patients with active pSpA over 12 weeks. Patients received open-label ADA for an additional 144 weeks. Twenty-nine enthesitis sites used in 3 enthesitis scoring systems [Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index, Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)] were assessed; discriminatory capacity and treatment response at Week 12 were calculated by standardized mean difference (SMD) and Guyatt's effect size (ES)...
March 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28293973/exploring-the-relationship-between-demographic-and-disease-related-variables-and-perceived-effect-of-health-status-on-sexual-activity-in-patients-with-axial-spondyloarthritis-associations-found-only-with-non-disease-variables
#3
K H Berg, G Rohde, A Prøven, E Almås, Eep Benestad, M Østensen, G Haugeberg
OBJECTIVE: To explore the relationship between demographic and disease-related variables and the perceived effect of health status on sexual activity in patients with axial spondyloarthritis (ax-SpA). METHOD: The study assessed 379 ax-SpA patients consecutively recruited from two rheumatology outpatient clinics. Data collection included information on demographics, markers and measures of ax-SpA disease, treatment, comorbidity, and health-related quality of life (HRQoL) using the Short Form-36...
March 15, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28270233/mechanistic-rationales-for-targeting-interleukin-17a-in-spondyloarthritis
#4
REVIEW
Siba P Raychaudhuri, Smriti K Raychaudhuri
The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis...
March 8, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28240587/evaluation-of-whether-extremely-high-enthesitis-or-bath-ankylosing-spondylitis-disease-activity-index-basdai-scores-suggest-fibromyalgia-and-confound-the-anti-tnf-response-in-early-non-radiographic-axial-spondyloarthritis
#5
Maxime Dougados, Isabelle Logeart, Annette Szumski, Javier Coindreau, Heather Jones
OBJECTIVES: Differentiating between pain from spondyloarthritis (SpA) and pain from fibromyalgia is challenging. We evaluated patients with non-radiographic axial SpA (nr-axSpA) to determine the percentage of patients with extremely high enthesitis and/or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, the relationship between extreme scores and depression, and the effect of extreme scores on treatment outcomes with etanercept. METHODS: Patients with nr-axSpA received double-blind etanercept 50 mg or placebo weekly and were divided into those who did vs did not have extreme scores at baseline...
February 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28216193/frequency-of-concomitant-fibromyalgia-in-rheumatic-diseases-monocentric-study-of-691-patients
#6
Angelique Fan, Bruno Pereira, Anne Tournadre, Zuzana Tatar, Sandrine Malochet-Guinamand, Sylvain Mathieu, Marion Couderc, Martin Soubrier, Jean-Jacques Dubost
OBJECTIVE: Fibromyalgia (FM) is a confounding factor for diagnosing and assessing rheumatic disease activity. This study sought to assess the extent of this syndrome in rheumatism patients at a French rheumatology department. METHOD: This monocentric epidemiological study enrolled all patients consulting due to rheumatoid arthritis (RA), spondyloarthritis (SpA), or connective tissue disease (CTD). FM diagnosis was confirmed or excluded according to the rheumatologist opinion and the 1990 American College of Rheumatology (ACR) criteria...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28197884/therapies-of-early-advanced-and-late-onset-forms-of-axial-spondyloarthritis-and-the-need-for-treat-to-target-strategies
#7
REVIEW
Nurullah Akkoc, Gercek Can, Salvatore D'Angelo, Angela Padula, Ignazio Olivieri
PURPOSE OF REVIEW: This study aims to provide an update on current status of pharmacological therapies in early and advanced stages of axial spondyloarthritis (axSpA), as well as its late onset forms, and to discuss the need for treat to target strategies in this entity. RECENT FINDINGS: Efficacy of TNF inhibitors has been assessed in randomized controlled trials in axSpA, which included patients who had non-radiographic axSpA according to the ASAS classification criteria...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28188227/the-hla-b27-peptidome-in-vivo-in-spondyloarthritis-susceptible-hla-b27-transgenic-rats-and-the-effect-of-erap1-deletion
#8
Eilon Barnea, Dganit Melamed Kadosh, Yael Haimovich, Nimman Satumtira, Martha L Dorris, Mylinh T Nguyen, Robert E Hammer, Tri M Tran, Robert A Colbert, Joel D Taurog, Arie Admon
HLA-B27 is a class I major histocompatibility (MHC-I) allele that confers susceptibility to the rheumatic disease ankylosing spondylitis (AS) by an unknown mechanism. ERAP1 is an aminopeptidase that trims peptides in the endoplasmic reticulum for binding to MHC-I molecules. ERAP1 shows genetic epistasis with HLA-B27 in conferring susceptibility to AS. Male HLA-B27 transgenic rats develop arthritis and serve as an animal model of AS, whereas female B27 transgenic rats remain healthy. We used large-scale quantitative mass-spectrometry to identify over 15,000 unique HLA-B27 peptide ligands, isolated after immunoaffinity purification of the B27 molecules from the spleens of HLA-B27 transgenic rats...
February 10, 2017: Molecular & Cellular Proteomics: MCP
https://www.readbyqxmd.com/read/28179619/rituximab-can-induce-remission-in-a-patient-with-ankylosing-spondylitis-who-failed-anti-tnf-%C3%AE-agent
#9
Fahmi AlDhaheri, Talal Almteri, Naji Dwid, Ahd Majdali, Nahed Janoudi, Hani Almoallim
BACKGROUND Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects the axial skeleton. The ability of anti-TNF-α agents to reduce disease activity in patients with axial spondyloarthritis (axSpA), including AS, has been demonstrated in multiple randomized trials and several meta-analyses. Reports on the efficacy of rituximab in treatment of AS have described good results. We report on a patient with AS who failed anti-TNF-α therapy but showed good clinical improvement with rituximab therapy...
February 9, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28176966/efficacy-and-safety-of-non-pharmacological-and-non-biological-pharmacological-treatment-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#10
COMMENT
Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety...
2017: RMD Open
https://www.readbyqxmd.com/read/28151874/single-nucleotide-polymorphisms-of-abcb1-gene-and-response-to-etanercept-treatment-in-patients-with-ankylosing-spondylitis-in-a-chinese-han-population
#11
Rui-Jian Yan, Ting-Ting Lou, Yi-Fang Wu, Wei-Shan Chen
BACKGROUND: Etanercept was highly recommended for patients with ankylosing spondylitis (AS), as its efficacy has been confirmed in AS, while genetic polymorphisms, by affecting drug metabolism or drug receptor, lead to interindividual variability in drug disposition and efficacy. Therefore, this study aims to investigate whether ABCB1 gene polymorphisms can predict therapeutic response to etanercept in patients with AS. METHODS: A total of 185 patients with AS in our hospital were recruited into our study from December 2012 to May 2015...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28149838/anti-il17a-in-axial-spondyloarthritis-where-are-we-at
#12
Peter P Cheung
Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically significant response. Secukinumab, a fully humanized monoclonal antibody targeting IL-17A, has recently been approved for use in patients with active ankylosing spondylitis...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28130206/tofacitinib-in-patients-with-ankylosing-spondylitis-a-phase-ii-16-week-randomised-placebo-controlled-dose-ranging-study
#13
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik
OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-ranging trial, adult patients with active AS were randomised (N=51, 52, 52, 52, respectively) to placebo or tofacitinib 2, 5 or 10 mg twice daily. The primary efficacy endpoint was Assessment of SpondyloArthritis International Society 20% improvement (ASAS20) response rate at week 12...
January 27, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28124744/-inflammatory-spinal-diseases-axial-spondyloarthritis-central-importance-of-imaging
#14
X Baraliakos, M Fruth, U Kiltz, J Braun
The diagnosis of axial spondyloarthritis (axSpA) includes classical ankylosing spondylitis (AS) as well as earlier stages and abortive courses of the disease, in which structural alterations have not yet occurred. These are classified as non-radiographic axSpA (nr-axSpa). Inflammatory changes in the entire axial skeleton are characteristic for axSpA and can be visualized by magnetic resonance imaging (MRI), while in most patients structural alterations, such as new bone formation with syndesmophytes and ankylosis develop in the later course of the disease...
January 26, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28123777/serum-inflammatory-biomarkers-fail-to-identify-early-axial-spondyloarthritis-results-from-the-spondyloarthritis-caught-early-space-cohort
#15
Maureen C Turina, Nataliya Yeremenko, Floris van Gaalen, Maikel van Oosterhout, Inger J Berg, Ramona Ramonda, Cristina M C Lebre, Robert Landewé, Dominique Baeten
INTRODUCTION: Decreasing the diagnostic delay in axial spondyloarthritis (axSpA) remains a major challenge. Here, we assessed the value of serum inflammatory biomarkers to distinguish early axSpA from other pathologies in a large cohort of patients referred with early back pain. METHODS: Serum c reactive protein (CRP), erythrocyte sedimentation rate (ESR) and calprotectin were determined in the SPondyloArthritis Caught Early (SPACE) cohort (n=310), an early back pain inception cohort...
2017: RMD Open
https://www.readbyqxmd.com/read/28121944/progression-rate-of-ankylosing-spondylitis-in-patients-with-undifferentiated-spondyloarthritis-a-systematic-review-and-meta-analysis
#16
REVIEW
Qing Xia, Dazhi Fan, Xiao Yang, Xiaona Li, Xu Zhang, Mengmeng Wang, Shengqian Xu, Faming Pan
BACKGROUND: The idea that undifferentiated spondyloarthritis (uSpA) represents the early undifferentiated stage of ankylosing spondylitis (AS) and other well-defined SpA subtypes is well known. The gist of this study is to assess the rate estimate of patients with uSpA evolved to AS during long-term follow-up. METHODS: A systematic search was implemented to identify pertinent articles. The primary outcome was the rate estimate that patients with uSpA fulfilling the diagnosis of AS according to the modified New York criteria during follow-up...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28110981/axial-spondyloarthritis
#17
REVIEW
Joachim Sieper, Denis Poddubnyy
The term axial spondyloarthritis covers both patients with non-radiographic and radiographic axial spondyloarthritis, which is also termed ankylosing spondylitis. The disease usually starts in the third decade of life with a male to female ratio of two to one for radiographic axial spondyloarthritis and of one to one for non-radiographic axial spondyloarthritis. More than 90% heritabilty has been estimated, the highest genetic association being with HLA-B27. The pathogenic role of HLA-B27 is still not clear although various hypotheses are available...
January 19, 2017: Lancet
https://www.readbyqxmd.com/read/28103205/is-the-use-of-agile-patency-capsule-prior-to-videocapsule-endoscopy-useful-in-all-patients-with-spondyloarthritis
#18
Andrada Gheorghe, Denise Carmen Mihaela Zahiu, Theodor Alexandru Voiosu, Bogdan Radu Mateescu, Mihail Radu Voiosu, Mihai Rimbaş
BACKGROUND AND AIMS: As already known, spondyloarthritis patients present a striking resemblance in intestinal inflammation with early Crohn's disease. Moreover, the frequent use of nonsteroidal anti-inflammatory drugs is an important part of their treatment. Both conditions could lead to intestinal stenoses. Therefore we proposed to investigate the usefulness of the patency capsule test in patients with spondyloarthritis. MATERIAL AND METHODS: 64 consecutive patients (33 males; mean age 38 ± 11 years) that fulfilled the AMOR criteria for seronegative spondyloarthropathy (59...
January 18, 2017: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/28099816/new-treatment-options-and-emerging-drugs-for-axial-spondyloarthritis-biological-and-targeted-synthetic-agents
#19
REVIEW
Eric Toussirot
Ankylosing spondylitis (AS) and axial spondyloarthritis (ax SpA) are chronic inflammatory diseases mainly involving the axial skeleton. Pharmacological treatments for AS and ax SpA usually include local glucocorticoid injections, NSAIDs and anti-TNFα agents. Since around 30% to 40% of patients are non responders or intolerant to anti-TNFα agents, we need new therapeutic options for AS and ax SpA. Areas covered: This review describes the new biological agents that can be used or are in development for AS or ax SpA as well as emerging synthetic targeted drugs...
February 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28087505/2016-update-of-the-asas-eular-management-recommendations-for-axial-spondyloarthritis
#20
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, Floris van Gaalen, Pál Géher, Irene van der Horst-Bruinsma, Robert D Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compàn, Salih Ozgocmen, Fernando M Pimentel-Santos, John Reveille, Martin Rudwaleit, Jochen Sieper, Percival Sampaio-Barros, Dieter Wiek, Jürgen Braun
To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009...
January 13, 2017: Annals of the Rheumatic Diseases
keyword
keyword
100428
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"